Artificial Blood Is Patient-Ready

In the midst of news that engineered organs are being implanted into animals and people, researchers announce the creation of artificial blood for transplant.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, ROB PONGSAJAPANA new source of blood could be just around the corner: red blood cells grown from fibroblasts that have been reprogrammed into mature red blood cells in the lab. The blood, developed by researchers at the University of Edinburgh and the Scottish National Blood Transfusion Service (SNBTS), would be Type O negative, also known as universal donor blood, which currently comprises just 7 percent of the blood donor pool.

“We have made red blood cells that are fit to go in a person’s body,” project leader Marc Turner, medical director at SNBTS, told Forbes. “Before now, we haven’t really had that.”

The blood is created by dedifferentiating fibroblasts from an adult donor and reprogramming them into induced pluripotent stem cells (iPSCs), which are then cultured in a bone-marrow-like environment for a month. Blood cells are then extracted from the cell culture. If the technique can be scaled up to industrial levels (which is no trivial task), beyond potentially supplying an endless supply of life-giving blood, the artificial blood would consist entirely of young, healthy, and infection-free cells, avoiding the issues of pathogen contamination that have in the past plagued the donor blood supply.

“Although ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies